ThromboGenics Eyes Name Change To Oxurion
Executive Summary
With Jetrea being a disappointment on the commercial front, the Belgian biotech will hope that a new name will augur well for its pipeline of disease modifying compounds for diabetic eye disease.
You may also be interested in...
Vision Failure Means End Of The Road For Oxurion
Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.
Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME
THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.